Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Sarcoma 1

Conditions

Sarcoma 4Gliosarcoma 4Glioblastoma 4Brain Neoplasms 3Ovarian Neoplasms 2Oligodendroglioma 2Breast Neoplasms 2Urologic Neoplasms 1Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Soft Tissue Neoplasms 1Sarcoma, Alveolar Soft Part 1Rhabdomyosarcoma 1Recurrence 1Prostatic Neoplasms 1Platinum-Refractory Fallopian Tube Carcinoma 1Pharyngeal Neoplasms 1Pancreatic Neoplasms 1Osteosarcoma 1Neurofibromatosis 2 1Neoplasms, Mesothelial 1Neoplasms 1Neoplasm Metastasis 1Mouth Neoplasms 1Melanoma 1Lymphangioleiomyomatosis 1Liposarcoma 1Leiomyosarcoma 1Hemangiosarcoma 1Glioma 1

Interventions

temsirolimus 1linrodostat 1ixabepilone 1Taxes 1Sunitinib 1Sirolimus 1Paclitaxel 1Nivolumab 1Laparoscopy 1Immunoglobulin G 1Epothilones 1Disulfides 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Adenocarcinoma × Disulfides × Sarcoma × Clear all
NCT00977574 2026-05-29

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
349 enrolled 11 charts
GynecologicSarcoma

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡